GlassScriptPhysician profile
Anjuli Sinha
NPI 1205231032
$2,882.08
in general payments reported to CMS, 2019-2025
22 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $338 · 2021: $225 · 2022: $39.37 · 2023: $441 · 2024: $554 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,106.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,133.14 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $511.74 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $383.47 | 2021-2025 | Vraylar |
| Novo Nordisk INC | $209.84 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $124.19 | 2020-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $120.11 | 2020-2023 | |
| Tempus Ai, INC | $58.31 | 2024-2025 | Tempus Pixel, Tempus Pixel |
| Genentech USA, INC. | $40.43 | 2020 | |
| Corium, LLC | $39.18 | 2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $34.77 | 2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $33.34 | 2020 | |
| Esperion Therapeutics, INC. | $31.78 | 2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.05 | 2025 | Jardiance |
| Exact Sciences Corporation | $19.36 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $18.44 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $18.08 | 2021 | |
| Abbott Laboratories | $16.24 | 2021 | |
| Pfizer INC. | $15.65 | 2023 | |
| Tearlab Corp | $15.46 | 2024 | Scoutpro Osmolarity System |
| Ibsa Pharma INC. | $13.94 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $12.56 | 2021 | |
| Glaxosmithkline, LLC. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjuli Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.